Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Frontiers in Pharma R&D Investment

Executive Summary

Given their diminishing R&D productivity, pharma companies have externalized more R&D in order to increase the number of drug projects and thus the chances of getting a major new product onto the market. But by and large, this externalization has used fairly traditional models, like product licensing, and hasn't fundamentally improved R&D's economics. Instead, these investment programs must increase the number of drug assets to which a pharmaceutical company has access - but without increasing to the same degree the capital or resource investment required to access them. Thus, a growing number of companies have begun to pursue new investment ideas that recognize that much of the value comes from having preferential access to the information needed to decide whether to exercise rights to programs - rather than day-to-day operational responsibilities. This article provides a framework for deciding among innovative models, and in particular, how to apply multiple approaches across an entire portfolio.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts